全文获取类型
收费全文 | 1247篇 |
免费 | 57篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 73篇 |
妇产科学 | 26篇 |
基础医学 | 103篇 |
口腔科学 | 23篇 |
临床医学 | 89篇 |
内科学 | 300篇 |
皮肤病学 | 36篇 |
神经病学 | 37篇 |
特种医学 | 33篇 |
外科学 | 221篇 |
综合类 | 28篇 |
预防医学 | 44篇 |
眼科学 | 41篇 |
药学 | 121篇 |
中国医学 | 63篇 |
肿瘤学 | 65篇 |
出版年
2024年 | 2篇 |
2023年 | 16篇 |
2022年 | 32篇 |
2021年 | 50篇 |
2020年 | 29篇 |
2019年 | 33篇 |
2018年 | 62篇 |
2017年 | 35篇 |
2016年 | 46篇 |
2015年 | 37篇 |
2014年 | 58篇 |
2013年 | 88篇 |
2012年 | 89篇 |
2011年 | 93篇 |
2010年 | 52篇 |
2009年 | 43篇 |
2008年 | 58篇 |
2007年 | 58篇 |
2006年 | 56篇 |
2005年 | 54篇 |
2004年 | 43篇 |
2003年 | 42篇 |
2002年 | 37篇 |
2001年 | 35篇 |
2000年 | 38篇 |
1999年 | 26篇 |
1998年 | 3篇 |
1997年 | 5篇 |
1996年 | 7篇 |
1995年 | 4篇 |
1992年 | 6篇 |
1991年 | 4篇 |
1990年 | 7篇 |
1989年 | 2篇 |
1988年 | 8篇 |
1987年 | 4篇 |
1986年 | 5篇 |
1985年 | 5篇 |
1983年 | 6篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1979年 | 7篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1975年 | 3篇 |
1973年 | 1篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1967年 | 1篇 |
1965年 | 2篇 |
排序方式: 共有1309条查询结果,搜索用时 15 毫秒
101.
102.
103.
104.
V U Ahmad M I Choudhary M F Akhtar M Ahmed G H Rizwani K Usmanghani J Clardy 《Journal of natural products》1990,53(4):960-963
An extract of the whole plant of Ruellia brittoniana has afforded the new glycoside 2-O-alpha-D-galactopyranosyl glycerol hexaacetate [1]. Its structure and absolute configuration were deduced by spectroscopic methods and X-ray crystallographic analysis. 相似文献
105.
106.
Shilpi Arora Irma M Gonzales R Tanner Hagelstrom Christian Beaudry Ashish Choudhary Chao Sima Raoul Tibes Spyro Mousses David O Azorsa 《Molecular cancer》2010,9(1):218
Background
Ewing's sarcomas are aggressive musculoskeletal tumors occurring most frequently in the long and flat bones as a solitary lesion mostly during the teen-age years of life. With current treatments, significant number of patients relapse and survival is poor for those with metastatic disease. As part of novel target discovery in Ewing's sarcoma, we applied RNAi mediated phenotypic profiling to identify kinase targets involved in growth and survival of Ewing's sarcoma cells. 相似文献107.
Defining outcomes for β‐cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop 下载免费PDF全文
Michael R. Rickels Peter G. Stock Eelco J. P. de Koning Lorenzo Piemonti Johann Pratschke Rodolfo Alejandro Melena D. Bellin Thierry Berney Pratik Choudhary Paul R. Johnson Raja Kandaswamy Thomas W. H. Kay Bart Keymeulen Yogish C. Kudva Esther Latres Robert M. Langer Roger Lehmann Barbara Ludwig James F. Markmann Marjana Marinac Jon S. Odorico François Pattou Peter A. Senior James A. M. Shaw Marie‐Christine Vantyghem Steven White 《Transplant international》2018,31(4):343-352
β‐cell replacement therapy, available currently as pancreas or islet transplantation, has developed without a clear definition of graft functional and clinical outcomes. The International Pancreas & Islet Transplant Association (IPITA) and European Pancreas & Islet Transplantation Association (EPITA) held a workshop to develop consensus for an IPITA/EPITA Statement on the definition of function and failure of current and future forms of β‐cell replacement therapy. There was consensus that β‐cell replacement therapy could be considered as a treatment for β‐cell failure, regardless of etiology and without requiring undetectable C‐peptide, accompanied by glycemic instability with either problematic hypoglycemia or hyperglycemia. Glycemic control should be assessed at a minimum by glycated hemoglobin (HbA1c) and the occurrence of severe hypoglycemia. Optimal β‐cell graft function is defined by near‐normal glycemic control [HbA1c ≤ 6.5% (48 mmol/mol)] without severe hypoglycemia or requirement for insulin or other antihyperglycemic therapy, and with an increase over pretransplant measurement of C‐peptide. Good β‐cell graft function requires HbA1c < 7.0% (53 mmol/mol) without severe hypoglycemia and with a significant (>50%) reduction in insulin requirements and restoration of clinically significant C‐peptide production. Marginal β‐cell graft function is defined by failure to achieve HbA1c < 7.0% (53 mmol/mol), the occurrence of any severe hypoglycemia, or less than 50% reduction in insulin requirements when there is restoration of clinically significant C‐peptide production documented by improvement in hypoglycemia awareness/severity, or glycemic variability/lability. A failed β‐cell graft is defined by the absence of any evidence for clinically significant C‐peptide production. Optimal and good functional outcomes are considered successful clinical outcomes. 相似文献
108.
109.
110.
Sachin Talwar M.Ch. Pranav Sharma M.S. Shiv Kumar Choudhary M.Ch. Balram Airan M.Ch. 《Journal of cardiac surgery》2010,25(3):357-358
Abstract We successfully used the ultrasonically activated scalpel to secure hemostasis in a temporary pacemaker‐dependent patient following repair of Ebstein's anomaly. The advantages of using this modality are briefly discussed. (J Card Surg 2010;25:357‐358) 相似文献